Clinical trials: Pick's Disease With Dementia
Frontotemporal Dementia
An Open-Label, Expanded Access Protocol of LAM-002A in C9ORF72-Associated Frontotemporal Dementia (FTD)
This is an open-label, single subject, expanded access protocol (EAP) of the LAM-002A investigational product administered orally at 125 mg BID for 52 weeks.
- Trial name
- NCT05483322
- Testing
- LAM-002A
- Sponsor
- IRulya Therapeutics Inc.
Progressive Supranuclear Palsy (PSP)
Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy
This is a phase 1, multi-center, double-blind, placebo-controlled, multiple dose escalation study with NIO752 in progressive supranuclear palsy (PSP) participants.
- Trial name
- NCT04539041
- Testing
- antisense oligonucleotide
- Where
- 12 sites in United States, Canada and 2 more
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals
Dementia, Alzheimer Disease
Incremental Diagnostic Value of Tau-PET With [18F]RO948 vs Amyloid-PET in Patients With Cognitive Impairment
The objective of the study is to investigate the clinical validity of tau-PET with [18F]RO948 vs. amyloid-PET in patients with Mild Cognitive Impairment (MCI) or mild dementia
- Trial name
- IDV of tau-PET (NCT06618872)
- Testing
- PET/CT with RO958 (experimental)
- Where
- 2 sites in Switzerland
- Volunteers
- 120 people
- Sponsor
- University Hospital, Geneva
Frontotemporal Dementia, Behavioral Variant Frontotemporal Dementia
Cognitive, Behavioral, and Functional Change in Behavioral Variant Frontotemporal Dementia (bvFTD)
The objectives of the study are to; (1) estimate the change in disease -related cognitive decline over 1 year on a battery of cognitive tests administered to participants with early-stage symptomatic Behavioral Variant…
- Trial name
- FORWARD (NCT03088956)
- Testing
- Assessments
- Where
- 12 sites in United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Biogen
Frontotemporal Dementia, Frontotemporal Degeneration
Voices Of Individuals: Challenges and Experiences Of bvFTD
The VOICE Of bvFTD study is a telephone interview research study about life with or at risk for behavioral variant frontotemporal dementia (bvFTD).
- Conditions
- Frontotemporal Dementia, Frontotemporal Degeneration, Frontotemporal Dementia, Behavioral Variant, FTD
- Trial name
- NCT04060082
- Testing
- Telephone Interview
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- University of Pennsylvania
Dementia, Dementia, Vascular
The Care Ecosystem Consortium Effectiveness Study
The Care Ecosystem is an accessible, remotely delivered team-based dementia care model, designed to add value for patients, providers and payers in complex organizational and reimbursement structures.
- Conditions
- Dementia, Dementia, Vascular, Dementia With Lewy Bodies, Dementia Alzheimers
- Trial name
- NCT05669365
- Testing
- Care Ecosystem
- Where
- 6 sites in United States
- Volunteers
- 1,227 people
- Sponsor
- University of California, San Francisco
Dementia Frontotemporal
Investigator Initiated Study for the Safety and Efficacy in Frontotemporal Dementia
The purpose of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD), immunogenicity, and efficacy of multiple intravenous administrations of the investigational drug NS101…
- Trial name
- NCT07154485
- Testing
- NS101 IV infusion
- Volunteers
- 15 people
- Sponsor
- Hee-Jin Kim
Amyotrophic Lateral Sclerosis, Alzheimer Disease
Neurodegenerative Alzheimer's Disease and Amyotrophic Lateral Sclerosis (NADALS) Basket Trial
This is an open-label, biomarker-driven basket trial of baricitinib in people with subjective cognitive disorder, mild cognitive impairment, Alzheimer's disease (AD), Amyotrophic lateral sclerosis (ALS), or asymptomatic carriers…
- Conditions
- Amyotrophic Lateral Sclerosis, Alzheimer Disease, Mild Cognitive Impairment
- Trial name
- NADALS (NCT05189106)
- Testing
- Baricitinib
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Massachusetts General Hospital
Insomnia, Dementia
Lemborexant for Insomnia in a Patient With Dementia: An N-of-1 Trial
Insomnia is a highly common, chronic disorder that is distressful for the patient but also for caregivers and can give rise to a heavy burden on the healthcare team.
- Conditions
- Insomnia, Dementia, Frontotemporal Dementia
- Trial name
- NCT06093126
- Testing
- Lemborexant 5 MG
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- Nova Scotia Health Authority